Debiopharm/TCGLS Collaborate To Develop Innovative Antibiotics For CHAIs

Debiopharm and TCG Lifesciences (TCGLS) have entered an exclusive discovery collaboration to develop innovative antibiotics targeting drug-resistant bacteria for community hospital-acquired infections (CHAIs). Under the terms of the agreement, TCGLS will contribute its expertise in the discovery and optimisation of lead compounds, whilst Debiopharm will provide drug development expertise and fund the development programme. Rolland-Yves Mauvernay, President and founder of Debiopharm, stated that TCGLS' extensive experience in medicinal chemistry and infectious diseases is a major asset for the development of Debio 1348.

Agreement Information:
Agreement Status: New Date Announced: 9 Sep 2013
Date Last Reported: Duration:
Est Total Value: Investment To Date:
Agreement Type: Development Research
Generic / Brand Name:
Therapeutic Area: General Anti-infectives Systemic
Indication: Bacterial infections Nosocomial infections
Techonology/Field: Drug development Drug discovery

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.